June 2, 2026Circulation
Response by Omland et al to Letter Regarding Article, “Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial”
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The SARAH trial is the first study to test sacubitril/valsartan as a cardioprotective strategy against anthracycline-induced cardiotoxicity, especially in high-risk patients.”
“If patients don't have preexisting heart conditions or high cardiovascular risks from the start — for example, hypertension or diabetes — it seems to be relatively safe to administer adjuvant therapy. In this patient group, the therapy isn't as dangerous as previously thought, and in general, patients should not be afraid that their cancer therapy will harm their heart.”
“What is critical to our field is to understand that we need to target cardioprotective therapy based on risk, and work on phenotyping patients according to their risk profile before treatment.”
Overview
Response addresses the impact of sacubitril/valsartan on cardiac dysfunction during breast cancer therapy, suggesting implications for treatment.
Key Points
- The response clarifies findings regarding the effects of sacubitril/valsartan in preventing cardiac dysfunction associated with breast cancer treatment.
- Discussion of results from the PRADA II randomized clinical trial.
- Focuses on the implications of therapy in the context of adjuvant treatment.
- Sacubitril/valsartan demonstrates potential benefits in reducing cardiac dysfunction risk during breast cancer adjuvant therapy.
- Specific event rates and effect sizes were not detailed in the response.
Cite This Study
Omland et al. (2026) studied this question.